Piotr Wysocki: Physical exercise – a new, promising neoadjuvant treatment modality in prostate cancer?
Piotr Wysocki recently posted on LinkedIn:
“A study published in JAMA Oncology analyzed the impact and feasibility of neoadjuvant exercise therapy in men with localized prostate cancer. This phase 1 decentralized, nonrandomized controlled trial explored the impact of exercise on 53 men with treatment-naive localized prostate cancer.
The trial, conducted at a single tertiary cancer center, utilized a patient-centric, decentralized platform. Participants engaged in six escalating doses of moderate-intensity treadmill walking, ranging from 90 to 450 minutes weekly. The primary aim was to determine the feasibility of the exercise doses and their effect on tumor cell proliferation and plasma prostate-specific antigen (PSA) levels.
All exercise dose levels were deemed feasible, with more than 75% of patients achieving the targeted relative exercise dose intensity (REDI). The study revealed that 225 minutes of exercise per week was particularly effective, significantly reducing the Ki67 proliferation marker and PSA levels. Specifically, the Ki67 changes for this exercise level were -1.3%, and PSA levels dropped by -0.5 ng/mL. Importantly, no serious adverse events were reported, underscoring the safety of the intervention.
The 225 minutes of weekly exercise was indicated as a recommended phase 2 dose.”
Authors: Lee W. Jones, Chaya S. Moskowitz, Catherine P. Lee, Gina A. Fickera, Su S. Chun, Meghan G. Michalski, Kurtis Stoeckel, Whitney P. Underwood, Jessica A. Lavery, Umeshkumar Bhanot, Irina Linkov, Chau T. Dang, Behfar Ehdaie, Vincent P. Laudone, James A. Eastham, Anne Collins, Patricia T. Sheerin, Lydia Y. Liu, Stefan E. Eng, and Paul C. Boutros
Source: Piotr Wysocki/LinkedIn
About Piotr Wysocki
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023